White House acknowledges Lilly chief's role in patent reform victory
This article was originally published in Scrip
After six years of lawmakers engaged in bartering, quibbling and wrangling, while corporate America and the academic community waited six long decades for change, a US president is enacting an historic overhaul of the nation's patent system on 16 September. But without the keen horse-trading skills of Lilly CEO Dr John Lechleiter and his willingness to give a little, that victory may not have happened this year, a White House official acknowledged.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.